Tissue-targeting RNA-LNP Development

• Advancements in Tissue-Specific RNA-LNP Delivery

  We always strive to improve our RNA-LNP delivery system so it can better target unhealthy tissues more successfully. This can mean producing different kind of mRNA Plasmid Manufacturing systems, but in terms of our latest progress we have been able to make RNA-LNP systems that will be applied in more ways. We can, thus, help multiple diseases of different tissues of an organ. For example there are treatments for lung diseases or even skin conditions.

• Developing RNA-LNP Delivery Systems to Target Tissue

  These RNA delivery systems have lifted the spirits of patients with those diseases that are localized to a particular tissue; Until now, there have been very limited options in treating these patients. Still, this breathtaking new technology has opened up a host of utterly novel directions for disease treatment that were once little more than science fiction.

• Providing Hope for Patients with Tissue-Specific Diseases

  In addition, potentially tissue-specific RNA-LNP platforms may be harnessed for T cell vaccine development. Similarly, we need the vaccines to be targetted at our lungs, so they will provide immune protection from other respiratory illnesses like SARS-CoV2. This result demonstrates the potential of saRNA-LNP Encapsulation Protocol technology not just as a therapeutic but also as prophylaxis to disease.

Why choose Yaohai Tissue-targeting RNA-LNP Development?

• Robust Supply Chain & Manufacturing Capabilities

  Yaohai Bio-Pharma, a top 10 manufacturer of biological products, is a specialist in microbial fermentation. We have established an efficient factory that has advanced facilities and robust RD and manufacturing capabilities. Five production lines for drug substances conforming to GMP standards for microbial fermentation and purification along with two fill and final lines for vials and cartridges and pre-filled needles are on offer. The available fermentation scales vary between 100L and Tissue-targeting RNA-LNP Development. Filling specifications for vias are 1ml up to 25ml. the pre-filled cartridge or syringe filling specifications are 1-3ml. The workshop for production is cGMP-compliant and provides that there is a steady supply of commercial and clinical samples. Our facility produces large molecules that are shipped worldwide.

• Professional Expertise & Extensive Experience

  Yaohai Bio-Pharma is a leading in Tissue-targeting RNA-LNP Development CDMO. Our main focus has been the production of microbial vaccinations and therapeutics to treat pets, human and veterinary health. We possess cutting-edge RD and manufacturing technology platforms that cover the entire manufacturing process from the engineering of microbial strains, to cell banking processing and method design to clinical and commercial manufacturing, making sure that we can ensure the successful delivery of the most advanced solutions. We have accumulated a huge quantity of knowledge in the bio processing microbial field. More than 200 projects have been successfully completed and we help our clients comply with regulations like those of the US FDA as well as EU EMA. We also help them to navigate Australia TGA and China NMPA. We are able to respond rapidly to market requirements and offer customized CDMO services due to our experience and expertise.

• Quality System & Global Regulatory Compliance

  Tissue-targeting RNA-LNP Development is a Top 10 Microbial CDMO that incorporates quality control and regulatory matters. We have established a robust quality system that complies with the current GMP standards and regulations all over the world. Our regulatory team is well-versed on global regulatory frameworks to speed up biological launches. We guarantee traceable production processes and top-quality products that are compliant with the rules of US FDA, EU EMA, Australia TGA, and China NMPA. Yaohai BioPharma successfully passed an audit on site conducted by an accredited Qualified Person from the European Union (QP) to review our GMP system and production facility. Additionally, we've passed the first certification audits of the ISO9001 Quality Management System, ISO14001 Environmental Management System, and ISO45001 Occupational Health and Safety Management System.

• Customization, Efficiency & Cost-Effectiveness

  Yaohai Bio-Pharma is experienced in the development of microbial-derived biologics. We offer customized RD as well as manufacturing solutions, while making sure that there are no risks. We have worked on diverse modalities such as subunit-based recombinant vaccines, Tissue-targeting RNA-LNP Development, cytokines, growth factors, single domain antibodies, enzymes, plasmid DNA, the mRNA, and other. We are experts in a variety of microorganisms, including yeast extracellular and intracellular secretion (yields up to 15g/L) as well as bacteria intracellular soluble and inclusion body (yields as high as 10g/L). We have also developed the BSL-2 fermentation platform to create bacteria-based vaccines. We have a track record of improving production processes, thereby increasing yields and decreasing costs. With a highly efficient technology team, we ensure timely and quality project delivery and bring your products to market faster.

Related product categories

• Analytical Methods for Plasmid DNA
• Bacteriophage AP205 VLP Manufacturing
• Bacteriophage Q VLP Manufacturing
• Chimeric VLP Vaccine Manufacturing
• Conjugate VLP Vaccines Manufacturing
• DNA Vaccine Manufacturing
• E. coli Fermentation for VLP Production
• GLP-1 Agonist Manufacturing
• GLP-1 Analog Manufacturing

Not finding what you're looking for?
Contact our consultants for more available products.